Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Gail Sloan, Macey Johnson, III, Matt Sargent, Howard McLeod


BioTheranostics has added three new employees to its senior management roster, including Gail Sloan as chief financial officer; Macey Johnson, III, as VP of managed care and reimbursement; and Matt Sargent as commercial leader of the Breast Cancer Index molecular test. These three will play a key role in BioTheranostics efforts to further expand commercial activities for its Breast Cancer Index product.

Prior to joining BioTheranostics, Sloan was CFO and VP of finance at La Jolla Pharmaceutical where she helped raise more than $330 million through private placements and public offerings. Johnson brings to BioTheranostics her many years of experience working in various roles at Genomic Health and Genentech. Sargent most recently was VP of oncology sales for Caris Life Sciences.

Howard McLeod is the new medical director of the Personalized Medicine Institute at the Moffitt Cancer Center. Previously, McLeod was the Fred Eshelman Distinguished Professor of Pharmacogenomics and Individualized Therapy at the University of North Carolina, Chapel Hill.

Additionally, he is the principal investigator for the CREATE Pharmacogenetics Research Network and a member of the Pharmacogenetics Research Network. McLeod directs the Pharmacogenetics for Every Nation Initiative, an effort that aims to help developing countries use genetic information to improve national drug formulary decisions.